One person without a cure is one person too many.
Call it blue-sky thinking, but we believe every patient deserves the chance of a cure. Our team of world-class infectious disease and liver disease experts are redefining today’s standards to reach new heights for patients globally.
About Bluejay Therapeutics
At Bluejay, we are discovering life-changing medicines and cures for people with viral and liver diseases, starting with chronic hepatitis B (CHB) and chronic hepatitis D (CHD).
Recent News, Posters, and Presentations
It’s personal
Bluejay is on a mission to illuminate a path toward curative treatments for serious viral and liver diseases.
At Bluejay, we each embody a passion and connection to our purpose, and we are unified in envisioning a world where a functional cure is possible for everyone with CHB/CHD. We believe it’s a question of when, not if.
Our Leadership
Our team combines decades of experience in HBV, virology, immunology and liver diseases with scientific integrity and a personal commitment to improve the lives of people living with these diseases.
We apply this knowledge to identify and develop highly differentiated assets that offer the greatest therapeutic potential with the lowest risk for patients.
Keting Chu
Founder and CEO/Chairman
Hassan Javanbakht
Chief Scientific Officer
Nancy Shulman
Chief Medical Officer
Kevin Lin
VP, Development
Jeff Zablocki
VP, Chemistry
Board of Directors
Keting Chu
Chairman of the Board
Wen Chen
Board member
Nancy Hong
Board member
Ting Jia
Board member
Alon Lazarus
Board member
Bill Rutter
Board member
Dajun Yang
Board member
Scientific Advisory Board
North America
Professor Jordan Feld
(U. Toronto, Canada)
Professor Norah Terrault
(USC, USA)
Europe
Professor Fabien Zoulim
(INSERM, France)
Professor Patrick Kennedy
(QMUL, UK)
Asia Pacific
Professor Ed Gane
(ACH, New Zealand)
Professor Jinlin Hou
(Southern Med. U., China)
Professor MF Yuen
(QMH, Hong Kong)
Board of Directors
Keting Chu
Chairman of the Board
Wen Chen
Board member
Nancy Hong
Board member
Ting Jia
Board member
Alon Lazarus
Board member
Bill Rutter
Board member
Dajun Yang
Board member
Scientific Advisory Board
North America
Professor Jordan Feld
(U. Toronto, Canada)
Professor Norah Terrault
(USC, USA)
Europe
Professor Fabien Zoulim
(INSERM, France)
Professor Patrick Kennedy
(QMUL, UK)
Asia Pacific
Professor Ed Gane
(ACH, New Zealand)
Professor Jinlin Hou
(Southern Med. U., China)
Professor MF Yuen
(QMH, Hong Kong)
Our Pipeline
Bluejay is passionate about shifting the treatment paradigms for patients with difficult viral and liver diseases.
We’re starting by making a functional cure for CHB a reality and developing a life-changing treatment for CHD – both have been in the shadow of other infectious diseases for too long.
